Assessment of topiramate’s efficacy and safety in epilepsy

Objective: To study the significance of topiramate (TPM) addition on seizure control in treatment of epilepsy. Design: A prospective open label add-on trial of TPM addition in patients with epilepsy was done. The events of baseline phase of 12 weeks followed by titration and maintenance phases were...

Full description

Bibliographic Details
Main Authors: Prem P. Gupta, Anup Kumar Thacker, Jamal Haider, Shilpi Dhawan, Neerjesh Pandey, Awanish Kumar Pandey
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2014-04-01
Series:Journal of Neurosciences in Rural Practice
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.131657
id doaj-d6954ebbdd624a51a66272c6d0af091b
record_format Article
spelling doaj-d6954ebbdd624a51a66272c6d0af091b2021-04-02T14:02:44ZengThieme Medical and Scientific Publishers Pvt. Ltd.Journal of Neurosciences in Rural Practice0976-31470976-31552014-04-0150214414810.4103/0976-3147.131657Assessment of topiramate’s efficacy and safety in epilepsyPrem P. Gupta0Anup Kumar Thacker1Jamal Haider2Shilpi Dhawan3Neerjesh Pandey4Awanish Kumar Pandey5Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, IndiaDepartment of Neurology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, IndiaDepartment of Pharmacology, Baba Raghav Das Medical College, Uttar Pradesh, IndiaDepartment of Pharmacology, Baba Raghav Das Medical College, Uttar Pradesh, IndiaDepartment of Pharmacology, TMC, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, IndiaDepartment of Pharmacy, ITM, Gorakhpur, Uttar Pradesh, IndiaObjective: To study the significance of topiramate (TPM) addition on seizure control in treatment of epilepsy. Design: A prospective open label add-on trial of TPM addition in patients with epilepsy was done. The events of baseline phase of 12 weeks followed by titration and maintenance phases were recorded. Assessment of the number of seizure and emergent adverse effects was done by a monthly visit for each case. Main Outcome Measures: Reduction of more than 50% mean seizure frequency or response ratio of 0.33 was taken as the criteria for responders. Statistical Analysis: Normal Z-test for significance of differences between two proportions and Chi-square test for presence of association was applied and mean age, median duration, sex ratio, percentage prevalence were depicted. Results: Significant responses to TPM in both partial as well as generalized seizures were observed (Z = 6.66, P < 0.001 and Z = 4.185, P < 0.01). The effect was more pronounced in patients with partial seizures. However, the overall response was highly significant (Z = 7.839, P < 0.001). The best response was noted at the dose of 200-300 mg/day (Z = 6.708, P < 0.001). More than 35% cases of partial and generalized seizures reported more than 75% reduction levels. The drug was well tolerated in more than 65% cases for side effects on psychosis, giddiness, and anorexia. Mild side effects were seen only in about less than 35% cases. Conclusions: TPM was found as a significantly effective add-on anticonvulsant with some limitation or mild side effects.http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.131657antiepileptic drugseizurestopiramate
collection DOAJ
language English
format Article
sources DOAJ
author Prem P. Gupta
Anup Kumar Thacker
Jamal Haider
Shilpi Dhawan
Neerjesh Pandey
Awanish Kumar Pandey
spellingShingle Prem P. Gupta
Anup Kumar Thacker
Jamal Haider
Shilpi Dhawan
Neerjesh Pandey
Awanish Kumar Pandey
Assessment of topiramate’s efficacy and safety in epilepsy
Journal of Neurosciences in Rural Practice
antiepileptic drug
seizures
topiramate
author_facet Prem P. Gupta
Anup Kumar Thacker
Jamal Haider
Shilpi Dhawan
Neerjesh Pandey
Awanish Kumar Pandey
author_sort Prem P. Gupta
title Assessment of topiramate’s efficacy and safety in epilepsy
title_short Assessment of topiramate’s efficacy and safety in epilepsy
title_full Assessment of topiramate’s efficacy and safety in epilepsy
title_fullStr Assessment of topiramate’s efficacy and safety in epilepsy
title_full_unstemmed Assessment of topiramate’s efficacy and safety in epilepsy
title_sort assessment of topiramate’s efficacy and safety in epilepsy
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
series Journal of Neurosciences in Rural Practice
issn 0976-3147
0976-3155
publishDate 2014-04-01
description Objective: To study the significance of topiramate (TPM) addition on seizure control in treatment of epilepsy. Design: A prospective open label add-on trial of TPM addition in patients with epilepsy was done. The events of baseline phase of 12 weeks followed by titration and maintenance phases were recorded. Assessment of the number of seizure and emergent adverse effects was done by a monthly visit for each case. Main Outcome Measures: Reduction of more than 50% mean seizure frequency or response ratio of 0.33 was taken as the criteria for responders. Statistical Analysis: Normal Z-test for significance of differences between two proportions and Chi-square test for presence of association was applied and mean age, median duration, sex ratio, percentage prevalence were depicted. Results: Significant responses to TPM in both partial as well as generalized seizures were observed (Z = 6.66, P < 0.001 and Z = 4.185, P < 0.01). The effect was more pronounced in patients with partial seizures. However, the overall response was highly significant (Z = 7.839, P < 0.001). The best response was noted at the dose of 200-300 mg/day (Z = 6.708, P < 0.001). More than 35% cases of partial and generalized seizures reported more than 75% reduction levels. The drug was well tolerated in more than 65% cases for side effects on psychosis, giddiness, and anorexia. Mild side effects were seen only in about less than 35% cases. Conclusions: TPM was found as a significantly effective add-on anticonvulsant with some limitation or mild side effects.
topic antiepileptic drug
seizures
topiramate
url http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.131657
work_keys_str_mv AT prempgupta assessmentoftopiramatesefficacyandsafetyinepilepsy
AT anupkumarthacker assessmentoftopiramatesefficacyandsafetyinepilepsy
AT jamalhaider assessmentoftopiramatesefficacyandsafetyinepilepsy
AT shilpidhawan assessmentoftopiramatesefficacyandsafetyinepilepsy
AT neerjeshpandey assessmentoftopiramatesefficacyandsafetyinepilepsy
AT awanishkumarpandey assessmentoftopiramatesefficacyandsafetyinepilepsy
_version_ 1721563326971904000